Levetiracetam monotherapy in juvenile myoclonic epilepsy

Seizure

Volumn 17, Issue 1, 2008, Pages 64-68

  Sharpe, Deron V ^a   Patel, Anup D ^a   Abou Khalil, Bassel ^a   Fenichel, Gerald M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Idiopathic generalized epilepsy; Juvenile myoclonic epilepsy; Levetiracetam; Monotherapy

Indexed keywords

CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; FOLLOW UP; HUMAN; MALE; MONOTHERAPY; MOOD DISORDER; MYOCLONUS EPILEPSY; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; DATA INTERPRETATION, STATISTICAL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MYOCLONIC EPILEPSY, JUVENILE; PIRACETAM; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 37149030106     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2007.07.001     Document Type: Article

References (17)

1. Panayiotopoulos C.P., Obeid T., and Tahan A.R. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia 35 (1994) 285-296
2. Kleveland G., and Engelsen B.A. Juvenile myoclonic epilepsy: clinical characteristics, treatment and prognosis in a Norwegian population of patients. Seizure 7 (1998) 31-38
3. Grunewald R.A., and Panayiotopoulos C.P. Juvenile myoclonic epilepsy. A review. Arch Neurol 50 (1993) 594-598
4. Dreifuss F.E. Juvenile myoclonic epilepsy: characteristics of a primary generalized epilepsy. Epilepsia 30 Suppl. 4 (1989) S1-S7 [Discussion S24-7]
5. Clement M.J., and Wallace S.J. Juvenile myoclonic epilepsy. Arch Dis Child 63 (1988) 1049-1053
6. Krauss G.L., Betts T., Abou-Khalil B., Gergey G., Yarrow H., and Miller A. Levetiracetam treatment of idiopathic generalised epilepsy. Seizure 12 (2003) 617-620
7. Abou-Khalil B., and Lazenby B. Long-term experience with levetiracetam. Epileptic Disord 5 Suppl. 1 (2003) S33-S37
8. Abou-Khalil B., Hemdal P., and Privitera M.D. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Seizure 12 (2003) 141-149
9. Lancman M.E., Asconape J.J., and Penry J.K. Clinical and EEG asymmetries in juvenile myoclonic epilepsy. Epilepsia 35 (1994) 302-306
10. Aliberti V., Grunewald R.A., Panayiotopoulos C.P., and Chroni E. Focal electroencephalographic abnormalities in juvenile myoclonic epilepsy. Epilepsia 35 (1994) 297-301
11. Atakli D., Sozuer D., Atay T., Baybas S., and Arpaci B. Misdiagnosis and treatment in juvenile myoclonic epilepsy. Seizure 7 (1998) 63-66
12. Prasad A., Kuzniecky R.I., Knowlton R.C., Welty T.E., Martin R.C., Mendez M., et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 60 (2003) 1100-1105
13. Patsalos P.N. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85 (2000) 77-85
14. Gower A.J., Hirsch E., Boehrer A., Noyer M., and Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22 (1995) 207-213
15. Gallagher M.J., Eisenman L.N., Brown K.M., Erbayat-Altay E., Hecimovic H., Fessler A.J., et al. Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 45 (2004) 90-91
16. Verdru P., Wajgt A., Schiemann Delgado J., and Noachtar S. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalised epilepsy with myoclonic seizures. Epilepsia 46 (2005) 56-57
17. Andermann E., Andermann F., Meyvisch P., Vandendriessche A., and Schiemann Delgado J. Seizure control with levetiracetam in juvenile myoclonic epilepsies. Epilepsia 46 Suppl. 8 (2005) 205